[Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women].
The use of botulinum toxin for the treatment of neurogenic detrusor overactivity was first described in 2000 and thereafter botulinum toxin has also been used in non-neurogenic overactive bladder. In current guidelines intravesical injection of onabotulinumtoxin A in refractory patients is recommended. Our aim is to provide some clinically relevant recommendations from the Working Group Urologische Funktionsdiagnostik und Urologie der Frau for diagnostics and treatment with onabotulinumtoxin A of patients with non-neurogenic overactive bladder.
Urologische Klinik und Poliklinik, Klinikum der Universität München - Campus Großhadern, Ludwig-Maximilians-Universität, Marchioninistraße 15, 81377, München, Deutschland, Ricarda.Bauer@med.uni-muenchen.de.
R M
RM
Bauer
C
C
Seif
T
T
Bschleipfer
A
A
Reitz
D
D
Schultz-Lampel
D000283:Administration, Intravesical; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014572:Urology / Q000592:standards*; D016387:Women's Health / Q000592:standards*
D019274:Botulinum Toxins, Type A